Patents by Inventor Andrew B. Benowitz

Andrew B. Benowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridines as DNMT1 inhibitors
    Patent number: 12285436
    Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
    Type: Grant
    Filed: July 26, 2023
    Date of Patent: April 29, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andrew B. Benowitz, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril, Megan Ketchum, Todd Koretke, Elizabeth Ann Moroz, Grace Price
  • SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS
    Publication number: 20240180933
    Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
    Type: Application
    Filed: July 26, 2023
    Publication date: June 6, 2024
    Inventors: Andrew B. BENOWITZ, David T. FOSBENNER, Bryan Wayne KING, Stuart Paul ROMERIL
  • Substituted pyridines as DNMT1 inhibitors
    Patent number: 11771711
    Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: October 3, 2023
    Assignee: GlaxoSmith Kline Intellectual Property Development Limited
    Inventors: Andrew B. Benowitz, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril
  • SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS
    Publication number: 20230101987
    Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
    Type: Application
    Filed: October 14, 2022
    Publication date: March 30, 2023
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andrew B. BENOWITZ, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril
  • Substituted pyridines as inhibitors of DNMT1
    Patent number: 10975056
    Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: April 13, 2021
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Cancer Research Technology Ltd.
    Inventors: Nicholas David Adams, Andrew B. Benowitz, María Lourdes Rueda Benede, Karen Anderson Evans, David T Fosbenner, Bryan Wayne King, Mei Li, Juan Ignacio Luengo, William Henry Miller, Alexander Joseph Reif, Stuart Paul Romeril, Stanley J. Schmidt, Roger J. Butlin, Kristin M. Goldberg, Allan M. Jordan, Christopher S. Kershaw, Ali Raoof, Bohdan Waszkowycz
  • SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1
    Publication number: 20190194166
    Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: June 13, 2017
    Publication date: June 27, 2019
    Inventors: Nicholas David ADAMS, Andrew B. BENOWITZ, María Lourdes Rueda BENEDE, Karen Anderson EVANS, David T. FOSBENNER, Bryan Wayne KING, Mei LI, Juan Ignacio LUENGO, William Henry MILLER, Alexander Joseph REIF, Stuart Paul ROMERIL, Stanley J. SCHMIDT, Roger J. BUTLIN, Kristen M. GOLDBERG, Allan M. JORDAN, Christopher S. KERSHAW, Ali RAOOF, Bohdan WASZKOWYCS
  • Peptide deformylase inhibitors
    Patent number: 8901119
    Abstract: The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: December 2, 2014
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Kelly M. Aubart, Andrew B. Benowitz, Yuhong Fang, James Hoffman, Joseph M. Karpinski, Andrew Nicholson Knox, Xiangmin Liao, Donghui Qin, Dongchuan Shi, Jared T. Spletstoser
  • PEPTIDE DEFORMYLASE INHIBITORS
    Publication number: 20130345120
    Abstract: The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.
    Type: Application
    Filed: March 9, 2012
    Publication date: December 26, 2013
    Applicant: Glaxosmithkline LLC
    Inventors: Kelly M. Aubart, Andrew B. Benowitz, Yuhong Fang, James Hoffman, Joseph M. Karpinski, Andrew Nicholson Knox, Xiangmin Liao, Donghui Qin, Dongchuan Shi, Jared T. Spletstoser
  • PEPTIDE DEFORMYLASE INHIBITORS
    Publication number: 20130045962
    Abstract: The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined below and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.
    Type: Application
    Filed: November 6, 2008
    Publication date: February 21, 2013
    Inventors: Donghui Qin, Beth Norton, Xiangmin Liao, Andrew Nicholson Knox, Jinhwa Lee, Yuhong Fang, Jason Christopher Dreabit, Siegfried Benjamin Christensen, IV, Andrew B. Benowitz, Kelly M. Aubart
  • Peptide deformylase inhibitors
    Patent number: 7919528
    Abstract: Novel PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: April 5, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Kelly M. Aubart, Andrew B. Benowitz, Siegfried B. Christensen, IV, Joseph M. Karpinski, Jinhwa Lee, Domingos J. Silva
  • Peptide deformylase inhibitors
    Patent number: 7507726
    Abstract: Novel PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: March 24, 2009
    Assignee: SmithKlineBeecham Corporation
    Inventors: Kelly M. Aubart, Andrew B. Benowitz, Siegfried B. Christensen, IV, Jinhwa Lee, Domingos J. Silva
  • Peptide Deformylase Inhibitors
    Publication number: 20080167302
    Abstract: Novel PDF inhibitors and novel methods for their use are provided.
    Type: Application
    Filed: August 12, 2004
    Publication date: July 10, 2008
    Inventors: Kelly M. Aubart, Andrew B. Benowitz, Siegfried B. Christensen IV, Jinhwa Lee, Domingos J. Silva
  • Oxazolidinones and methods for the synthesis and use of same
    Patent number: 6034247
    Abstract: Synthetic methods for pyrrolinone-based compounds are provided. Such compounds mimic or inhibit the biological and/or chemical activity of peptides.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: March 7, 2000
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Amos B. Smith, III, Ralph F. Hirschmann, Paul A. Sprengeler, Andrew B. Benowitz, David A. Favor